Gene editing and its application for hematological diseases

Mark J. Osborn; Joseph J. Belanto; Jakub Tolar; Daniel F. Voytas

doi:10.1007/s12185-016-2017-z

Gene editing and its application for hematological diseases

Mark J. Osborn, Joseph J. Belanto, Jakub Tolar, Daniel F. Voytas

Research output: Contribution to journal › Review article › peer-review

19 Scopus citations

Abstract

The use of precise, rationally designed gene-editing nucleases allows for targeted genome and transcriptome modification, and at present, four major classes of nucleases are being employed: zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), meganucleases (MNs), and clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9. Each reagent shares the ability to recognize and bind a target sequence of DNA. Depending on the properties of the reagent, the DNA can be cleaved on one or both strands, or epigenetic changes can be mediated. These novel properties can impact hematological disease by allowing for: (1) direct modification of hematopoietic stem/progenitor cells (HSPCs), (2) gene alteration of hematopoietic lineage committed terminal effectors, (3) genome engineering in non-hematopoietic cells with reprogramming to a hematopoietic phenotype, and (4) transcriptome modulation for gene regulation, modeling, and discovery.

Original language	English (US)
Pages (from-to)	18-28
Number of pages	11
Journal	International Journal of Hematology
Volume	104
Issue number	1
DOIs	https://doi.org/10.1007/s12185-016-2017-z
State	Published - Jul 1 2016

Bibliographical note

Funding Information:
MJO and JT appreciate funding support from The Children's Cancer Research Fund, the Epidermolysis Bullosa Research Partnership, Epidermolysis Bullosa Medical Research Fund, Sohana Research Fund, Richard M Schulze Family Foundation, DebRA, the Lindahl Family, and the Corrigan Family. JT is supported in part by R01 AR063070, R01 AR059947, DOD W81XWH-12-1-0609, and P01 CA065493. MJO is supported by 8UL1TR000114-02. JB is supported by a grant from the National Science Foundation to DV (IOS-1339209). Research reported in this publication was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health Award Number UL1TR000114 (MJO). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Funding Information:
MJO and JT appreciate funding support from The Children’s Cancer Research Fund, the Epidermolysis Bullosa Research Partnership, Epidermolysis Bullosa Medical Research Fund, Sohana Research Fund, Richard M Schulze Family Foundation, DebRA, the Lindahl Family, and the Corrigan Family. JT is supported in part by R01 AR063070, R01 AR059947, DOD W81XWH-12-1-0609, and P01 CA065493. MJO is supported by 8UL1TR000114-02. JB is supported by a grant from the National Science Foundation to DV (IOS-1339209). Research reported in this publication was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health Award Number UL1TR000114 (MJO). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Publisher Copyright:
© 2016, The Japanese Society of Hematology.

Keywords

Blood disorders
CRISPR/Cas9
Hematopoiesis
Hematopoietic stem cells
TALEN
ZFN

Publisher link

10.1007/s12185-016-2017-z

Find It

Find It at U of M Libraries

Cite this

@article{d4816ff0919b4cac942c903867a01748,

title = "Gene editing and its application for hematological diseases",

abstract = "The use of precise, rationally designed gene-editing nucleases allows for targeted genome and transcriptome modification, and at present, four major classes of nucleases are being employed: zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), meganucleases (MNs), and clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9. Each reagent shares the ability to recognize and bind a target sequence of DNA. Depending on the properties of the reagent, the DNA can be cleaved on one or both strands, or epigenetic changes can be mediated. These novel properties can impact hematological disease by allowing for: (1) direct modification of hematopoietic stem/progenitor cells (HSPCs), (2) gene alteration of hematopoietic lineage committed terminal effectors, (3) genome engineering in non-hematopoietic cells with reprogramming to a hematopoietic phenotype, and (4) transcriptome modulation for gene regulation, modeling, and discovery.",

keywords = "Blood disorders, CRISPR/Cas9, Hematopoiesis, Hematopoietic stem cells, TALEN, ZFN",

author = "Osborn, {Mark J.} and Belanto, {Joseph J.} and Jakub Tolar and Voytas, {Daniel F.}",

note = "Funding Information: MJO and JT appreciate funding support from The Children's Cancer Research Fund, the Epidermolysis Bullosa Research Partnership, Epidermolysis Bullosa Medical Research Fund, Sohana Research Fund, Richard M Schulze Family Foundation, DebRA, the Lindahl Family, and the Corrigan Family. JT is supported in part by R01 AR063070, R01 AR059947, DOD W81XWH-12-1-0609, and P01 CA065493. MJO is supported by 8UL1TR000114-02. JB is supported by a grant from the National Science Foundation to DV (IOS-1339209). Research reported in this publication was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health Award Number UL1TR000114 (MJO). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Funding Information: MJO and JT appreciate funding support from The Children{\textquoteright}s Cancer Research Fund, the Epidermolysis Bullosa Research Partnership, Epidermolysis Bullosa Medical Research Fund, Sohana Research Fund, Richard M Schulze Family Foundation, DebRA, the Lindahl Family, and the Corrigan Family. JT is supported in part by R01 AR063070, R01 AR059947, DOD W81XWH-12-1-0609, and P01 CA065493. MJO is supported by 8UL1TR000114-02. JB is supported by a grant from the National Science Foundation to DV (IOS-1339209). Research reported in this publication was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health Award Number UL1TR000114 (MJO). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Publisher Copyright: {\textcopyright} 2016, The Japanese Society of Hematology.",

year = "2016",

month = jul,

day = "1",

doi = "10.1007/s12185-016-2017-z",

language = "English (US)",

volume = "104",

pages = "18--28",

journal = "International Journal of Hematology",

issn = "0925-5710",

publisher = "Springer Japan",

number = "1",

}

TY - JOUR

T1 - Gene editing and its application for hematological diseases

AU - Osborn, Mark J.

AU - Belanto, Joseph J.

AU - Tolar, Jakub

AU - Voytas, Daniel F.

N1 - Funding Information: MJO and JT appreciate funding support from The Children's Cancer Research Fund, the Epidermolysis Bullosa Research Partnership, Epidermolysis Bullosa Medical Research Fund, Sohana Research Fund, Richard M Schulze Family Foundation, DebRA, the Lindahl Family, and the Corrigan Family. JT is supported in part by R01 AR063070, R01 AR059947, DOD W81XWH-12-1-0609, and P01 CA065493. MJO is supported by 8UL1TR000114-02. JB is supported by a grant from the National Science Foundation to DV (IOS-1339209). Research reported in this publication was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health Award Number UL1TR000114 (MJO). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Funding Information: MJO and JT appreciate funding support from The Children’s Cancer Research Fund, the Epidermolysis Bullosa Research Partnership, Epidermolysis Bullosa Medical Research Fund, Sohana Research Fund, Richard M Schulze Family Foundation, DebRA, the Lindahl Family, and the Corrigan Family. JT is supported in part by R01 AR063070, R01 AR059947, DOD W81XWH-12-1-0609, and P01 CA065493. MJO is supported by 8UL1TR000114-02. JB is supported by a grant from the National Science Foundation to DV (IOS-1339209). Research reported in this publication was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health Award Number UL1TR000114 (MJO). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Publisher Copyright: © 2016, The Japanese Society of Hematology.

PY - 2016/7/1

Y1 - 2016/7/1

N2 - The use of precise, rationally designed gene-editing nucleases allows for targeted genome and transcriptome modification, and at present, four major classes of nucleases are being employed: zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), meganucleases (MNs), and clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9. Each reagent shares the ability to recognize and bind a target sequence of DNA. Depending on the properties of the reagent, the DNA can be cleaved on one or both strands, or epigenetic changes can be mediated. These novel properties can impact hematological disease by allowing for: (1) direct modification of hematopoietic stem/progenitor cells (HSPCs), (2) gene alteration of hematopoietic lineage committed terminal effectors, (3) genome engineering in non-hematopoietic cells with reprogramming to a hematopoietic phenotype, and (4) transcriptome modulation for gene regulation, modeling, and discovery.

AB - The use of precise, rationally designed gene-editing nucleases allows for targeted genome and transcriptome modification, and at present, four major classes of nucleases are being employed: zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), meganucleases (MNs), and clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9. Each reagent shares the ability to recognize and bind a target sequence of DNA. Depending on the properties of the reagent, the DNA can be cleaved on one or both strands, or epigenetic changes can be mediated. These novel properties can impact hematological disease by allowing for: (1) direct modification of hematopoietic stem/progenitor cells (HSPCs), (2) gene alteration of hematopoietic lineage committed terminal effectors, (3) genome engineering in non-hematopoietic cells with reprogramming to a hematopoietic phenotype, and (4) transcriptome modulation for gene regulation, modeling, and discovery.

KW - Blood disorders

KW - CRISPR/Cas9

KW - Hematopoiesis

KW - Hematopoietic stem cells

KW - TALEN

KW - ZFN

UR - http://www.scopus.com/inward/record.url?scp=84970971336&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84970971336&partnerID=8YFLogxK

U2 - 10.1007/s12185-016-2017-z

DO - 10.1007/s12185-016-2017-z

M3 - Review article

C2 - 27233509

AN - SCOPUS:84970971336

SN - 0925-5710

VL - 104

SP - 18

EP - 28

JO - International Journal of Hematology

JF - International Journal of Hematology

IS - 1

ER -

Gene editing and its application for hematological diseases

Abstract

Bibliographical note

Keywords

Publisher link

Find It

Other files and links

Fingerprint

Cite this